Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$269M |
| 2 |
Amazon
AMZN
|
+$242M |
| 3 |
Apple
AAPL
|
+$215M |
| 4 |
Amgen
AMGN
|
+$212M |
| 5 |
Citizens Financial Group
CFG
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$210M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$195M |
| 3 |
iShares GSCI Commodity Dynamic Roll Strategy ETF
COMT
|
+$154M |
| 4 |
MXIM
Maxim Integrated Products
MXIM
|
+$127M |
| 5 |
WORK
Slack Technologies, Inc.
WORK
|
+$115M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.58% |
| 2 | Financials | 13.47% |
| 3 | Healthcare | 12.09% |
| 4 | Consumer Discretionary | 10.78% |
| 5 | Industrials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2701
Sutro Biopharma
STRO
$353M
| $2.04M | ﹤0.01% |
10,787
+387
| +4% | +$73.6K |
|
|
AFMD
2702
DELISTED
Affimed
AFMD
| $2.04M | ﹤0.01% |
32,924
-4,640
| -12% | -$305K |
|
2703
Regis Corp
RGS
$70.1M
| $2.04M | ﹤0.01% |
29,228
-513
| -2% | -$67.4K |
|
|
BCOV
2704
DELISTED
Brightcove, Inc.
BCOV
| $2M | ﹤0.01% |
173,629
+2,423
| +1% | +$29.3K |
|
|
DMTK
2705
DELISTED
DermTech, Inc. Common Stock
DMTK
| $2M | ﹤0.01% |
62,320
+3,247
| +5% | +$114K |
|
|
TCRR
2706
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $1.98M | ﹤0.01% |
232,051
+37,480
| +19% | +$530K |
|
2707
McEwen Inc
MUX
$1.14B
| $1.95M | ﹤0.01% |
187,299
+44,904
| +32% | +$515K |
|
2708
Atlanta Braves Holdings Series A
BATRA
$3.64B
| $1.92M | ﹤0.01% |
71,301
-230
| -0.3% | -$6.14K |
|
2709
Fulcrum Therapeutics
FULC
$283M
| $1.9M | ﹤0.01% |
67,348
+13,064
| +24% | +$248K |
|
|
CCRN
2710
DELISTED
Cross Country Healthcare
CCRN
| $1.9M | ﹤0.01% |
89,214
+458
| +0.5% | +$8.59K |
|
2711
KRONOS Worldwide
KRO
$996M
| $1.89M | ﹤0.01% |
152,513
+1,355
| +0.9% | +$17.9K |
|
2712
Century Therapeutics
IPSC
$349M
| $1.89M | ﹤0.01% |
+75,076
| New | +$2.03M |
|
|
SPNS
2713
DELISTED
Sapiens International
SPNS
| $1.89M | ﹤0.01% |
65,624
+95
| +0.1% | +$2.6K |
|
|
ONTF
2714
DELISTED
ON24
ONTF
| $1.89M | ﹤0.01% |
94,640
+33,553
| +55% | +$932K |
|
|
HGEN
2715
DELISTED
HUMANIGEN, INC.
HGEN
| $1.89M | ﹤0.01% |
317,917
-5,420
| -2% | -$76.1K |
|
2716
The Honest Company
HNST
$540M
| $1.88M | ﹤0.01% |
180,825
+3,339
| +2% | +$40.8K |
|
2717
Intapp
INTA
$3.16B
| $1.87M | ﹤0.01% |
+72,746
| New | +$2.36M |
|
|
LGTY
2718
DELISTED
Logility Supply Chain Solutions, Inc. Common Stock
LGTY
| $1.87M | ﹤0.01% |
78,850
+1,382
| +2% | +$31.8K |
|
|
BASE
2719
DELISTED
Couchbase
BASE
| $1.87M | ﹤0.01% |
+60,059
| New | +$2.21M |
|
|
VIA
2720
DELISTED
Via Renewables, Inc. Class A Common Stock
VIA
| $1.82M | ﹤0.01% |
35,799
-1,012
| -3% | -$56.1K |
|
|
RXDX
2721
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $1.8M | ﹤0.01% |
75,711
+583
| +0.8% | +$13.8K |
|
|
NOTV
2722
DELISTED
Inotiv
NOTV
| $1.79M | ﹤0.01% |
61,270
+29,008
| +90% | +$844K |
|
2723
State Street SPDR Portfolio Short Term Treasury ETF
SPTS
$6.12B
| $1.79M | ﹤0.01% |
58,426
-268
| -0.5% | -$8.22K |
|
|
DAWN
2724
DELISTED
Day One Biopharmaceuticals
DAWN
| $1.79M | ﹤0.01% |
+75,226
| New | +$1.8M |
|
2725
Monte Rosa Therapeutics
GLUE
$1.35B
| $1.78M | ﹤0.01% |
+79,974
| New | +$2.29M |
|
Similar funds
Charles Schwab's Q3 2021 Portfolio in Review
As of Q3 2021, Charles Schwab held 3,610 positions worth $306B, up 1.6% from $301B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Charles Schwab's Q3 2021 filing shows 202 new, 2,185 increased, 922 reduced and 109 closed positions. Its largest new stake was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M. The largest sale was Vanguard FTSE Emerging Markets ETF, an estimated $210M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q3 2021 buy was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M.
- Charles Schwab added most to Moderna in Q3 2021, an estimated $269M increase.
- Charles Schwab's biggest Q3 2021 reduction was Vanguard FTSE Emerging Markets ETF, cutting an estimated $210M.
- Charles Schwab fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $195M.
- Charles Schwab's ten largest holdings make up 17% of its $306B portfolio in Q3 2021.
- Charles Schwab opened 202 new positions and closed 109 in Q3 2021.
- Charles Schwab's portfolio value rose 1.6% quarter-over-quarter to $306B.
Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.